OCGN - how to play the COVAXIN news !OCGN:
What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken – double-check me on it – except AstraZeneca all of them need cooling. The vaccine of Ocugen is in cooperation with Bharat Biotech. the vaccine is supposed to be stronger against different strains of covid that are emerging …. The reason for all the noise is in the fine print -they closed a damn good deal on the sales in the U.S – they will receive 45% of profits with no upfront payment (someone was drunk when he agreed to that deal LOL)… so price target given by Roth Capital is 8$ -don’t agree – I think in the next year if all goes well this stock is above 15$ if we factor in the “meme” market going on could be much more and much faster but let's stay conservative.
Ok lets talk shop – technical:
POC (point of control) is not good – 3,18 but I am certain it will rise in the upcoming week – remember POC is like a “magnet” it will attract the price to it for obvious reason.
Volume: average volume is 63M, last 2 days trading above 100M.
50% line of retracement is 3.95 (round it up to the 4$ area – its always areas not specific numbers ) which means we will need to see the golden number getting touched sooner or later (again consider “meme” market conditions are extremely abnormal)
4.5$ -6$ needs to be retested – there needs to be a retracement to that area with some sideways trend before we can say let’s see 8$ - in normal market conditions….
Notice on the chart the yellow square showing ling upper wicks meaning buying power got very weak – matches the volume orders on the left (the colors are somewhat faded meaning it needs accumulation), reversal signal.
The red box in the lower part of the chart is the forbidden zone – it is the other side of the POC and the stock flew through that price too quick so if we see a pullback to the POC line we may see a sell-off to that area- don’t believe this will happen so soon as sentiment is very high
Bottom line – I think we need to see some pull back the upcoming days before the stock goes higher to the next level of 7$-usually happens after a 2-3 days rally and once that is done we can target 7$+.
Please keep in mind we are trading on a very speculative market and everything is highly inflated along with 1.9T $ coming and meme trend this is a very risky market and using my analysis on it can mean shit because it is NOT BEHAVING like it should at all !!
FDGT will wait for a pullback before entering as the trend doesn’t look healthy
This is not a recommendation of any sort
Trader safe and be safe – we are the traders union and we trade by our own rules!
OCGN trade ideas
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market.
Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market.
Ocugen and Bharat Biotech to share US commercialization profits.
Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US.
COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients.
COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape.
today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market.
Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market .
B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits.
In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program.
H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market.
Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements.
Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday.
Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
$OCGN PT 6-12 and higherOcugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
$OCGN is gonna fall todayPupm&Dump trading strategy idea.
$OCGN is rising without clear preconditions today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $0,449;
stop-loss — $0,512;
take-profit — $0,323;
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Fourth FDA Orphan Drug Designation for OCU400 (AAV-NR2E3)Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases
The FDA Office of Orphan Products Development grants orphan designation for novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. Orphan designation qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including a seven-year period of U.S. marketing exclusivity, tax credits for clinical research costs, clinical research trial design assistance, the ability to apply for annual grant funding and waiver of Prescription Drug User Fee Act filing fees.
finance.yahoo.com
Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease
Third orphan drug designation for the same product
finance.yahoo.com
TWITTER
It seems they received a Notice of Allowance for ANOTHER U.S. patent and just paid their fee last week. I assume we will hear about this too in addition to their latest orphan drug status designation? They have a lot of good news. A bit of insider purchases in May too.
I assume they will announce both soon. Typically no pr is made until the notice of issue is granted with the patent number & grant date. This happens shortly after the notice of allowance is granted and the fee is received (& other minor administrative items are completed).
It has not even started clinical trials yet! Face with tears of joy Lol!! orphan drug status means the costs to test and develop will be substantially subsidized by the government for public policy reasons. So this is basically an announcement that they received a free $150M.
According to the FDA website, $OCGN just received orphan drug status to complete its OCU400 modifier gene therapy platform! I have not seen any PR yet. They will also present at the World Orphan Drug Congress next month.
OCUGEN MAJOR BULL RUN INCOMING!Hey guys!
A lot of you may not know this but I actually do some stock trading on the side as well as creating YouTube videos.
Recently I came across this stock and honestly in my past 5 years of trading I have never come across something that looks more of an attractive buy than this stock...OCUGEN!
And I'm going to explain why for a number of reasons.
1) We can see a clear elliot wave 1 & 2 being completed with a 0.618 retracement on the fibonacci
2) As the retracement was heavy for wave 2, we can expect the retracement for wave 4 to be less and indeed we do see this as wave 3 hits a peak and wave 4 retraces to the 0.382
3) Wave 5 is sure to be a fruitful wave! Take a look at everything from the RSI showing an amazing trend line on the 30 minute & histogram now ticking to the positive on the hourly
4) Lastly...switch over to monthly. THERE HASN'T BEEN VOLUME LIKE THIS IN MONTHS!
Definitely bullish and I'll be keeping an eye out for a breakout past the triangle.
Happy trading!